Table 6.
Association of CD14 and HLA-DOA methylation (measured as percentage of methylated cytosine) with common colorectal carcinoma biomarkers (KRAS, BRAF, MSI)
| Biomarker* | CD14 | HLA-DOA | |||||
|---|---|---|---|---|---|---|---|
| Median | IR | p value | Median | IR | p value | ||
| KRAS | Mutated | 9.20 | 5.9 | 35.97 | 38.8 | ||
| Wild-type | 15.355 | 12 | 0.022 | 40.37 | 33.7 | 0.290 | |
| BRAF | Mutated | 16.68 | 21.7 | 39.63 | 35.5 | ||
| Wild-type | 12.845 | 6.4 | 0.035 | 37.53 | 36.2 | 0.82 | |
| MSI | Unstable | 16.7 | 19.1 | 40.95 | 30.2 | ||
| Stable | 11.32 | 6.1 | 0.001 | 31.9 | 39.6 | 0.069 | |
*Codon 12 and 13 mutations in KRAS and V600E mutation in BRAF were considered. CpG site 2 for CD14 and CpG site 2 for HLA-DOA were considered. Similar results were obtained for site 1 (data not shown)
IR interquartile range, MSI microsatellite instability